Referral patterns in advanced non-small cell lung cancer: Impact on delivery of treatment and survival in a contemporary population based cohort

Lung Cancer

Volumn 86, Issue 3, 2014, Pages 344-349

  Noonan, Krista ^a   Tong, King Mong ^a   Laskin, Janessa ^a   Melosky, Barbara ^a   Sun, Sophie ^a   Murray, Nevin ^a   Ho, Cheryl ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Advanced NSCLC; Population based analysis; Referral patterns; Treatment delivery

Indexed keywords

CARBOPLATIN; CISPLATIN; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PATIENT REFERRAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RURAL AREA; TREATMENT DURATION; TREATMENT OUTCOME; URBAN AREA; VERY ELDERLY; CARCINOMA, NON-SMALL-CELL LUNG; HEALTH SURVEY; KAPLAN MEIER METHOD; LUNG NEOPLASMS; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POPULATION SURVEILLANCE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REFERRAL AND CONSULTATION; RETROSPECTIVE STUDIES;

EID: 84926190086     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.09.016     Document Type: Article

References (29)

1. Siegel R., Ma J., Zou Z., et al. Cancer statistics, 2014. CA Cancer J Clin 2014, 64:9-29.
2. Canadian cancer Society's committee on cancer statistics: Canadian cancer statistics 2013. Toronto, Ontario, Canada, Canadian Cancer Society; 2013.
3. Siegel R., Ward E., Brawley O., et al. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011, 61:212-236.
4. Govindan R., Page N., Morgensztern D., et al. Changing epidemiology of small-cell lung cancer in the united states over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006, 24:4539-4544.
5. Nair A., Klusmann M.J., Jogeesvaran K.H., et al. Revisions to the TNM staging of non-small cell lung cancer: Rationale, clinicoradiologic implications, and persistent limitations. Radiographics 2011, 31:215-238.
6. Johnson D.H., Schiller J.H., Bunn P.A. Recent clinical advances in lung cancer management. J Clin Oncol 2014, 32:973-982.
7. Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer. Cochrane Database Syst Rev 2010, (5). Non-Small Cell Lung Cancer Collaborative Group, doi: CD007309.
8. Chemotherapy in addition to supportive care improves survival in advanced Non-Small-cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008, 26:4617-4625. NSCLC Meta-Analyses Collaborative Group.
9. Rapp E., Pater J.L., Willan A., et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a canadian multicenter randomized trial. J Clin Oncol 1988, 6:633-641.
10. Mok T.S., Wu Y., Thongprasert S., et al. Gefitinib or Carboplatin-Paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
11. Shaw A.T., Kim D.W., Nakagawa K., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013, 368:2385-2394.
12. Quoix E., Zalcman G., Oster J.P., et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet 2011, 378:1079-1088.
13. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. the elderly lung cancer vinorelbine italian study group. J Natl Cancer Inst 91:66-72, 1999.
14. Gridelli C., Perrone F., Gallo C., et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: The multicenter italian lung cancer in the elderly study (MILES) phase III randomized trial. J Natl Cancer Inst 2003, 95:362-372.
15. Zukin M., Barrios C.H., Pereira J.R., et al. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and eastern cooperative oncology group performance status of 2. J Clin Oncol 2013, 31:2849-2853.
16. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.
17. Goulart B.H.L., Reyes C.M., Fedorenko C.R., et al. Referral and treatment patterns among patients with stages III and IV Non-Small-cell lung cancer. J Oncol Pract 2013, 9:42-50.
18. Ritzwoller D.P., Carroll N.M., Delate T., et al. Patterns and predictors of first-line chemotherapy use among adults with advanced non-small cell lung cancer in the cancer research network. Lung Cancer 2012, 78:245-252.
19. Rasco D.W., Yan J., Xie Y., et al. Looking beyond surveillance, epidemiology, and end results: Patterns of chemotherapy administration for advanced non-small cell lung cancer in a contemporary, diverse population. J Thorac Oncol 2010, 5:1529-1535.
20. Patel N., Adatia R., Mellemgaard A., et al. Variation in the use of chemotherapy in lung cancer. Br J Cancer 2007, 96:886-890.
21. Azzoli C.G., Temin S., Aliff T., et al. 2011 focused update of 2009 american society of clinical oncology clinical practice guideline update on chemotherapy for stage IV Non-Small-cell lung cancer. J Clin Oncol 2011, 29:3825-3831.
22. Hutchins L.F., Unger J.M., Crowley J.J., et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999, 341:2061-2067.
23. Murthy V.H., Krumholz H.M., Gross C.P. Participation in cancer clinical trials: Race-, sex-, and age-based disparities. JAMA 2004, 291:2720-2726.
24. Falk S.J., Girling D.J., White R.J., et al. Immediate versus delayed palliative thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancer and minimal thoracic symptoms: randomised controlled trial. BMJ 2002, 325:465.
25. Salomaa E.R., Sallinen S., Hiekkanen H., et al. Delays in the diagnosis and treatment of lung cancer. Chest 2005, 128:2282-2288.
26. Diaconescu R., Lafond C., Whittom R. Treatment delays in non-small cell lung cancer and their prognostic implications. J Thorac Oncol 2011, 6:1254-1259.
27. Myrdal G., Lambe M., Hillerdal G., et al. Effect of delays on prognosis in patients with non-small cell lung cancer. Thorax 2004, 59:45-49.
28. Ellis P.M., Vandermeer R. Delays in the diagnosis of lung cancer. J Thorac Dis 2011, 3:183-188.
29. Wai E.S., Mackinnon M., Hooker R., et al. Wait times in diagnostic evaluation and treatment for patients with stage III non-small cell lung cancer in british columbia. Am J Clin Oncol 2012, 35:373-377.